Lentitek develops enabling technologies aimed at improving the manufacturability and quality of cell and gene therapies, with a particular focus on supporting next‑generation in‑vivo CAR‑T treatments. The company says interest in its solutions has been driven by therapies moving from lab to clinic where quality is critical. Over the past year Lentitek transitioned from R&D to revenue-generating and signed several significant deals while building a larger commercial pipeline. Management positions the business to capitalise on demand for capabilities that aid manufacturability and quality in advanced therapies. Financially, Lentitek completed an equity raise of £725,000 led by Equity Gap and is conducting an ongoing fundraising process to provide working capital to convert its pipeline. The company characterized the funding as strengthening its finances to accelerate commercialisation.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2026